Efficiency of tocilizumab therapy for an exacerbation of systemic lupus erythematosus: A case report and a review of literature
Interleukin-6 (IL-6) is one of the major proinflammatory cytokines, which, by interacting with hepatocytes, induces the synthesis of a broad spectrum of acute phase inflammatory proteins. IL-6 plays an important role in the development and progression of systemic lupus erythematosus (SLE), participa...
Saved in:
Main Authors: | S. K. Solovyev, A. A. Mesnyankina, D. E. Karateev, E. L. Luchikhina, Ya. A. Sigidin, E. A. Aseeva, A. V. Elonakov, E. L. Nasonov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2017-09-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/780 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
INNOVATIVE TREATMENTS FOR TAKAYASU’S ARTERITIS: A FOCUS ON INTERLEUKIN-6 INHIBITORS. THE AUTHORS’ EXPERIENCE WITH TOCILIZUMAB AND A REVIEW OF LITERATURE
by: T. V. Beketova, et al.
Published: (2017-10-01) -
THE EFFICIENCY OF BIOLOGICAL THERAPY AND THE FEATURES OF HUMORAL IMMUNITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
by: A. A. Mesnyankina, et al.
Published: (2018-07-01) -
Anti-B cell therapy in patients with systemic lupus erythematosus
by: M. E. Tsanyan, et al.
Published: (2018-01-01) -
EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY
by: T. V. Beketova, et al.
Published: (2018-05-01) -
Sequential therapy with rituximab and belimumab in patients with systemic lupus erythematosus
by: A. A. Mesnyankina, et al.
Published: (2020-11-01)